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ABSTRACT
Introduction Hospital- acquired thrombosis accounts for a 
large proportion of all venous thromboembolism (VTE), with 
significant morbidity and mortality. This subset of VTE can 
be reduced through accurate risk assessment and tailored 
pharmacological thromboprophylaxis. This systematic 
review aimed to determine the comparative accuracy 
of risk assessment models (RAMs) for predicting VTE in 
patients admitted to hospital.
Methods A systematic search was performed across five 
electronic databases (including MEDLINE, EMBASE and 
the Cochrane Library) from inception to February 2021. All 
primary validation studies were eligible if they examined 
the accuracy of a multivariable RAM (or scoring system) 
for predicting the risk of developing VTE in hospitalised 
inpatients. Two or more reviewers independently 
undertook study selection, data extraction and risk of bias 
assessments using the PROBAST (Prediction model Risk Of 
Bias ASsessment Tool) tool. We used narrative synthesis to 
summarise the findings.
Results Among 6355 records, we included 51 studies, 
comprising 24 unique validated RAMs. The majority of 
studies included hospital inpatients who required medical 
care (21 studies), were undergoing surgery (15 studies) 
or receiving care for trauma (4 studies). The most widely 
evaluated RAMs were the Caprini RAM (22 studies), Padua 
prediction score (16 studies), IMPROVE models (8 studies), 
the Geneva risk score (4 studies) and the Kucher score (4 
studies). C- statistics varied markedly between studies and 
between models, with no one RAM performing obviously 
better than other models. Across all models, C- statistics 
were often weak (<0.7), sometimes good (0.7–0.8) and 
a few were excellent (>0.8). Similarly, estimates for 
sensitivity and specificity were highly variable. Sensitivity 
estimates ranged from 12.0% to 100% and specificity 
estimates ranged from 7.2% to 100%.
Conclusion Available data suggest that RAMs have 
generally weak predictive accuracy for VTE. There is 
insufficient evidence and too much heterogeneity to 
recommend the use of any particular RAM.
PROSPERO registration number Steve Goodacre, 
Abdullah Pandor, Katie Sworn, Daniel Horner, Mark Clowes. 
A systematic review of venous thromboembolism RAMs for 
hospital inpatients. PROSPERO 2020 CRD42020165778. 
Available from https://www. crd. york. ac. uk/ prospero/ 
display_ record. php? RecordID= 165778 https:// www. crd. 
york. ac. uk/ prospero/ display_ record. php? RecordID= 165778
INTRODUCTION
Venous thromboembolism (VTE) is an 
important and life- threatening complication 
of hospitalisation and illness, and is associated 
with significant morbidity and mortality.1 2 
Globally, an estimated 10 million VTE episodes 
are diagnosed each year; over half of these 
episodes are associated with hospital inpa-
tients stays and result in significant loss of 
disability- adjusted life years.3 4 Consequently, 
there has been a substantial and sustained 
focus on VTE prevention over the last three 
decades, with good evidence indicating a 
reduction in morbidity with primary throm-
boprophylaxis in hospitalised patients.5–8 
Despite this evidence, thromboprophylaxis 
remains either underused or inappropriately 
applied.9
Risk assessment models (RAMs) have been 
developed to help stratify the risk of VTE 
among hospitalised patients.10 These models 
use clinical information from the patient’s 
history and examination to identify those 
with an increased risk of developing VTE who 
are most likely to benefit from pharmacolog-
ical prophylaxis. Inappropriate use of VTE 
Strengths and limitations of this study
 ► This systematic review provides an up- to- date 
comprehensive review of risk assessment models 
for predicting venous thromboembolism in patients 
admitted to hospital.
 ► The newly developed PROBAST (Prediction model 
Risk Of Bias ASsessment Tool) tool was used to eval-
uate the risk of bias and applicability of the available 
evidence.
 ► Heterogeneity in the included studies (participants, 
inclusion criteria, clinical condition, outcome defi-
nition and measurement) and variable reporting of 
items precluded meta- analysis.
 ► Limitations of the existing evidence and areas of fu-
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prophylaxis may not reduce VTE rates and may cause 
unnecessary harm.11 While RAMs could improve the ratio 
of benefit to risk and benefit to cost, it is unclear which 
VTE RAM should be applied to guide decision- making 
for prophylaxis in clinical practice and thereby optimise 
patient care.
The current review extends and updates three broadly 
overlapping existing reviews.10 12 13 While these reviews 
identified the use of various (derived and validated) 
RAMs for VTE in hospitalised patients, they did not find 
any evidence to suggest which RAM was superior. The aim 
of this systematic review was to identify primary validation 
studies (as derivation studies may give an overoptimistic 
assessment of model performance measures) and deter-
mine the accuracy of individual RAMs for predicting the 
risk of developing VTE in hospital inpatients.
METHODS
A systematic review was undertaken in accordance with 
the general principles recommended in the Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses (PRISMA) statement.14 This review was part of 
a larger project on VTE RAMs for hospital inpatients15 
and was registered on the International Prospective 
Register of Systematic Reviews (PROSPERO) database 
(CRD42020165778).
Eligibility criteria
We sought studies evaluating RAMs which could be 
applied to a general inpatient population (medical, 
surgical or trauma) rather than disease- specific models. 
All primary validation studies that evaluated the accu-
racy (eg, sensitivity, specificity, C- statistic) of a multi-
variable RAM (or scoring system) for predicting the 
risk of developing VTE were eligible for inclusion. We 
selected studies that included validation of the model 
in a group of patients that were not involved in model 
derivation. This involved either splitting the study 
cohort (internal) or using a new cohort (external). The 
study could have reported derivation of the model but 
we only used the validation data to estimate accuracy. 
The study population consisted of hospital inpatients 
including those who required medical care, under-
going any surgery (excluding day surgery) or received 
care following an injury. Studies that primarily focused 
on children (aged under 16 years), women admitted to 
hospital for pregnancy- related reasons and any patient 
admitted to a level 2 or above critical care environment 
(eg, patients requiring more detailed observation or 
intervention including support for a single failing organ 
system or postoperative care and those ‘stepping down’ 
from higher levels of care) were excluded. These patient 
groups have VTE risk profiles that differ markedly from 
the general inpatient population, making the use of a 
generic model inappropriate.
Data sources and searches
Potentially relevant studies were identified through 
searches of five electronic databases including MEDLINE 
(with MEDLINE In- process and Epub Ahead of Print), 
EMBASE and the Cochrane Library. The search strategy 
used free text and thesaurus terms and combined 
synonyms relating to the condition (eg, VTE in medical 
inpatients) with risk prediction modelling terms. No 
language restrictions were used. However, as the current 
review updated three previous systematic reviews,10 12 13 
searches were limited by date from 2017 (last search date 
from earlier reviews)10 to February 2021. Searches were 
supplemented by hand- searching the reference lists of all 
relevant studies (including existing systematic reviews); 
forward citation searching of included studies; contacting 
key experts in the field; and undertaking targeted searches 
of the World Wide Web using the Google search engine. 
Further details on the search strategy can be found in 
online supplemental appendix S1.
Study selection
All titles were examined for inclusion by one reviewer 
(KS) and any citations that clearly did not meet the inclu-
sion criteria (eg, non- human, unrelated to VTE inpa-
tients) were excluded. All abstracts and full- text articles 
were then examined independently by two reviewers (KS 
and AP). Any disagreements in the selection process were 
resolved through discussion or if necessary, arbitration by 
a third reviewer (SG) and included by consensus.
Data extraction and quality assessment
Data relating to study design, methodological quality and 
outcomes were extracted by one reviewer (KS) into a stan-
dardised data extraction form and independently checked 
for accuracy by a second (AP or MT). Any discrepancies 
were resolved through discussion to achieve agreement. 
Where differences were unresolved, a third reviewer’s 
opinion was sought (SG). Where multiple publications of 
the same study were identified, data were extracted and 
reported as a single study.
The methodological quality of each included study was 
assessed using PROBAST (Prediction model Risk Of Bias 
ASsessment Tool).16 17 This instrument evaluates four key 
domains: patient selection, predictors, outcome and anal-
ysis. Each domain is assessed in terms of risk of bias and 
the concern regarding applicability to the review (first 
three domains only). To guide the overall domain- level 
judgement about whether a study is at high, low or an 
unclear (in the event of insufficient data in the publica-
tion to answer the corresponding question) risk of bias, 
subdomains within each domain include a number of 
signalling questions to help judge with bias and applica-
bility concerns. An overall risk of bias for each individual 
study was defined as low risk when all domains were 
judged as low; and high risk of bias when one or more 
domains were considered as high. Studies were assigned 
an unclear risk of bias if one or more domains were 















































































































3Pandor A, et al. BMJ Open 2021;11:e045672. doi:10.1136/bmjopen-2020-045672
Open access
Data synthesis and analysis
We were unable to perform meta- analysis due to signif-
icant levels of heterogeneity between studies (partici-
pants, inclusion criteria, clinical condition) and variable 
reporting of items. As a result, a prespecified narrative 
synthesis approach18 19 was undertaken, with data being 
summarised in tables with accompanying narrative 
summaries that included a description of the included 
variables, statistical methods and performance measures 
(eg, sensitivity, specificity and C- statistic (a value between 
0.7 and 0.8 and >0.8 indicated good and excellent discrim-
ination, respectively; and values <0.7 were considered 
weak20), where applicable. All analyses were conducted 
using Microsoft Excel V.2010 (Microsoft Corporation, 
Redmond, Washington, USA).
Patient and public involvement
Patients and the public were not involved in the design or 
conduct of this systematic review.
RESULTS
Study flow
Figure 1 summarises the process of identifying and 
selecting relevant literature. Of the 6355 citations iden-
tified, 51 studies investigating 24 unique RAMs met 
the inclusion criteria. The majority of the articles were 
excluded primarily for not using a RAM for predicting 
the risk of developing VTE, having no useable or rele-
vant outcome data or an inappropriate study design (eg, 
derivation study, reviews, commentaries or editorials). A 





































































































































































Table 1 Study and population characteristics













Autar, 200322 UK P,CS Single 148 Hospitalised patients from 
orthopaedic, medical and 
surgical specialties
NR NR 50%  ► Novel (Autar, 
2003)
DVT, not defined 
(90 days)
18.9% External
Rogers et al, 
200756
USA P,CS Multi 91 308 Hospitalised surgical 
patients (undergoing 
vascular and general 
surgery)
NR NR NR  ► Novel (Rogers et 
al, 2007)
VTE (30 days) 0.6% Internal: split (half)
Abdel- Razeq et 
al, 201021
Jordan P,CS Single 606 Hospitalised (>24 hours) 
cancer patients aged ≥18 
years
51 51% 55%  ► Caprini (modified) VTE, symptomatic 
(60 days)
3.5% External
Bahl et al, 201023 USA R,CS Multi 8216 Hospitalised surgical 
patients (undergoing 
general, vascular and 
urologic surgery)
NR NR NR  ► Caprini VTE (30 days) 1.4% External
Barbar et al, 
201024
Italy P,CS Single 1180 Hospitalised medical 
patients
NR 47% 16%  ► Padua VTE, symptomatic 
(90 days)
3.1% External
Rothberg et al, 
201158
USA R,CS Multi 48 540 Hospitalised (≥3 days) 
medical patients aged 
≥18 years




0.5% Internal: split 
(20%)
Woller et al, 
201169
USA R,CS Multi 46 856 Hospitalised medical 
patients aged ≥18 years
61 46% NR  ► Intermountain
 ► Kucher
VTE, defined by 
ICD-9 codes (90 
days)
4.5% Internal: split 
(25%)




R,CS Multi 5761 Hospitalised (>2 days) 
patients with a burn injury 
aged ≥18 years
46 69% NR  ► Novel (Panunucci 
et al, 2012)
VTE, not defined 
(NR)
1.0% Internal: split 
(25%)
Rogers et al, 
201255
USA R,CS Multi 234 032 Hospitalised trauma 
patients
NR NR NR  ► TESS VTE (NR) NR Internal: split
Bilimoria et al, 
201325
USA R,CS Multi 88 053 Hospitalised surgical 
patients (undergoing 
colorectal surgery)
NR NR NR  ► ACS NSQIP—
Colon specific
 ► ACS 
NSQIP—Universal
DVT, not defined 
(30 days)
2.3% External: split (by 
year)
Hegsted et al, 
201339
USA R,CS Single 2281 Hospitalised (≥2 days) 
trauma patients aged ≥13 
years
45 70% NR  ► RAP DVT, not defined or 
PE (NR)
 ► DVT: 
10.5%
 ► PE: 
1.5%
External
Vardi et al, 
201364
Israel P,CS Single 1080 Hospitalised (≥2 days) 
sepsis patients aged >18 
years
75 52% 18%  ► Padua VTE, hospital 
associated (NR)
1.3% External
Ho et al, 201441 Australia R,CS Single 357 Hospitalised major trauma 
patients
NR 75% NR  ► TESS VTE, symptomatic 
(NR)
20.7% External
Liu et al, 201444 China P,CS Single 287 Hospitalised acute stroke 
patients aged >18 years
NR 63% 22%  ► Post- stroke DVT 
prediction system
DVT (14±3 days) 10.5% Internal: split 
(33%)
Continued



































































Mahan et al, 
201447
USA CC Multi 417 Hospitalised (≥3 days) 
medical patients aged 
≥18 years






Nendaz et al, 
201451
Switzerland P,CS Multi 1478 Hospitalised (>24 hours) 
medical patients aged 
≥18 years
65 53% 57%  ► Geneva
 ► Padua
VTE, symptomatic 
including PE or 
DVT (90 days)
2.0% External
Pannucci et al, 
201452
USA P,CS Multi 3576 Hospitalised surgical 
patients aged ≥18 years
NR NR 66%  ► Novel (Panunucci 
et al, 2014)
VTE (90 days) 1.4% Internal: split 
(35%)
Rosenberg et al, 
201457
USA CC Multi 19 217 Hospitalised (≥3 days) 
medical patients aged 
≥18 years
NR 47% 43%  ► IMPROVE 
(7- factor)
VTE, defined by 
ICD-9 codes (90 
days)
NA External
Zhou et al, 
201471
China CC Single 998 Hospitalised (≥2 days) 
medical patients aged 
>18 years
NR 58% 15%  ► Caprini
 ► Padua
VTE, defined by 
ICD-10 codes (NR)
NA External
Hewes et al, 
201540
USA R,CS Single 70 Hospitalised cancer 
patients (undergoing 
oesophagectomy)
NR 83% 96%  ► Caprini (modified) VTE (60 days) 14.3% External
de Bastos et al, 
201632
Brazil P,CS Single 11 091 Hospitalised medical 
patients aged >18 years
50 61% 0%  ► Caprini VTE, symptomatic 
(NR)
0.3% External
Grant et al, 
201636
USA R,CS Multi 63 548 Hospitalised (≥2 days) 
medical patients aged 
≥18 years




Greene et al, 
201637
USA R,CS Multi 63 548 Acutely ill, hospitalised 
(≥2 days) medical patients 
aged ≥18 years









Hachey et al, 
201638




pneumonectomy for lung 
cancer)
NR 43% 92%  ► Caprini VTE (60 days) 5.2% External
Lui et al, 201645 China CC Single 640 Hospitalised (>2 days) 
medical patients aged 
≥18 years
NR 52% NR  ► Caprini
 ► Padua
VTE (NR) N/A External
Lobastov et al, 
201646




69 49% 100%  ► Caprini DVT or PE, new 
(NR)
27.9% External
Shaikh et al, 
201659
USA R,CS Multi 1598 Hospitalised surgical 
patients (undergoing 
plastic surgery)









































































Elias et al, 
201734
USA R,CS Single 30 726 Hospitalised (>2 days) 
medical and surgical 
patients
NR 44% 21%  ► Padua 
(automated)
VTE, defined by 
ICD-9 codes (NR)
0.8% External
Frankel et al, 
2017 (abstract)35
USA CC NR 149 Hospitalised surgical 




NR NR NR  ► Caprini VTE, not defined 
(90 days)
NA External
Krasnow et al, 
2017 (abstract)43
USA R,CS Multi 1 099 093 Hospitalised surgical 
patients (major urological 
cancer surgery)
NR NR NR  ► Caprini VTE, symptomatic 
(90 days)
1.2% External
Patell et al, 
201754
USA R,CS Single 2780 Hospitalised (>24 hours) 




56% 65%  ► Khorana VTE, defined by 
ICD-9 codes (NR)
3.8% External
Winoker et al, 
201768
USA R,CS Multi 300 Hospitalised surgical 
patients (undergoing 
urological surgery using 




62% NR  ► ACS 
NSQIP—Universal
VTE, not defined 
(NR)
0.3% External
Blondon et al, 
201828
Switzerland P,CS Multi 1478 Hospitalised (>24 hour) 
medical patients aged 
≥18 years
65 53% 59%  ► IMPROVE 
(7- factor)
 ► Geneva †
 ► Padua †
VTE, symptomatic 
including PE or 
DVT (90 days)
2.0% External
Chen et al, 
201830
China CC Single 390 Hospitalised (>2 days) 
patients aged ≥18 years 
with and without DVT
NR 51% 41%  ► Caprini
 ► Padua
DVT (NR) NA External
Dornbus et al, 
2018 (abstract)33
USA R,CS NR 2830 Hospitalised surgical 
patients (undergoing 
neurosurgery)
NR NR NR  ► Caprini VTE, not defined 
(NR)
NR External
Vaziri et al, 
201865
USA R,CS Single 1006 Hospitalised surgical 
patients (undergoing 
neurosurgery)
NR 46% NR  ► ACS 
NSQIP- Universal
VTE, not defined 
(NR)
1.3% External
Vincentelli et al, 
201866
Italy CC Multi 1215 Acutely ill, hospitalised 
medical patients aged 
>18 years
NR 44% NR  ► Chopard
 ► Kucher
 ► Padua
VTE (NR) NA External
Zhou et al, 
201870
China CC Single 1804 Hospitalised (≥2 days) 
medical patients aged 
>18 years
NR 59% 5%  ► Caprini
 ► Padua
VTE, defined by 
ICD-10 codes (NR)
NA External
Blondon et al, 
2019a26
Italy R,CS* Single 1180 Hospitalised medical 
patients








Switzerland R,CS * Multi 991 Hospitalised elderly 
medical patients
75 55% NR  ► Geneva 
(simplified)










































































Cobben et al, 
201931
Netherlands CC Multi 556 Hospitalised (>24 hours) 
medical patients
NR 52% NR  ► Caprini
 ► Geneva
 ► IMPROVE 
(4- factor)






 ► NICE Guideline
 ► Padua
 ► PRETEMED 
guideline
 ► Zakai et al (model 
2)
VTE (NR) NA External
Tachino et al, 
201962
Japan R,CS Multi 859 Hospitalised (>24 hours) 
trauma patients aged ≥18 
years
NR 64% NR  ► RAP
 ► Quick RAP
VTE (NR) 3.0% External (RAP)/
internal (qRAP)
Tian et al, 201963 China R,CS Single 533 Hospitalised surgical 
patients (undergoing 
thoracic surgery)
53 53% 0%  ► Caprini
 ► Khorana
 ► Padua
 ► Novel (Rogers et 
al, 2007)
VTE (NR) 8.4% External
Bo et al, 202029 China P,CS Multi 24 524 Hospitalised (≥2 days) 
patients from medical and 
surgical specialties aged 
≥18 years
57 57 NR  ► Caprini DVT (NR) 0.9% External
Hu et al, 202042 China CC Single 442 Hospitalised (≥2 days) 
cancer patients aged ≥18 
years
NR 62 3.8  ► Caprini
 ► Khorana
VTE, defined by 
ICD-10 codes (NR)
NA External
Mlaver et al, 
202048




transplant or general 
surgery)
NR NR NR  ► Caprini
 ► Padua
VTE, not defined 
(NR)
NA External
Moumneh et al, 
202049
France R,CS * Multi 14 660 Acutely ill, hospitalised 
(≥2 days) medical patients 
aged ≥40 years
73 50 46.1  ► Caprini
 ► Padua
 ► IMPROVE (7 
factor)
VTE, symptomatic 
including PE or 
DVT (90 days)
1.8% External
Nafee et al, 
202050
35 countries R,CS * Multi 6459 Hospitalised medical 
patients
76 45 100  ► IMPROVE (NR)
 ► Novel (Nafee et 
al, 2020a)
 ► Novel (Nafee et 
al, 2020b)
VTE (77 days) 6.3% External
Table 1 Continued
Continued
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full list of excluded studies with reasons for exclusion is 
provided in online supplemental appendix S2.
Study and patient characteristics
The design and participant characteristics of 
the 51 included studies21–71 are summarised in 
table 1. All studies were published between 2003 
and 2020 and were undertaken in North America 
(n=24),23 25 33–40 43 47 48 52–59 65 68 69 Asia (n=13),29 30 42 44–46 60–63 67 70 71 
Europe (n=9),22 24 26–28 31 49 51 66 the Middle- East (n=2),21 64 
South America (n=1),32 Australia (n=1)41 and one study 
was intercontinental.50 Sample sizes ranged from 7040 to 
1 099 09343 patients in 37 observational cohort studies (11 
prospective21 22 24 28 29 32 44 51 52 56 64 (5 of which were multicentre) 
and 26 retrospective23 25–27 33 34 36–41 43 46 49 50 53–55 58 59 62 63 65 68 69 
(16 of which were multicentre) in design). Sample sizes 
in 14 case–control studies30 31 35 42 45 47 48 57 60 61 66 67 70 71 (4 
of which were multicentre) ranged from 14861 to 19 21757 
patients.
The vast majority of studies evaluated VTE risk assess-
ment in hospital inpatients who required medical care 
(n=21),24 26–28 31 32 36 37 45 47 49–51 57 58 61 66 67 69–71 were under-
going surgery (n=15)23 25 33 35 38 40 43 46 48 52 56 59 63 65 68 or were 
a mixed medical and surgical cohort (n=4).22 29 30 34 The 
remaining studies focused on patients receiving care for 
trauma (n=4),39 41 55 62 cancer (n=4),21 42 54 60 stroke (n=1),44 
burn injuries (n=1)53 and sepsis (n=1).64 The mean age 
ranged from 45 years39 to 76 years50 (not reported in 29 
studies)22–25 30 31 33–35 38 40–45 47 48 52 55–58 61 62 65 66 70 71 and 
the proportion of female subjects ranged from 17%40 to 
81%59 (not reported in 12 studies).22 23 25 33 35 43 48 52 55 56 58 61
VTE definition and case ascertainment
The majority of studies 
(n=37)21 23 24 26–32 36–38 40–47 49–52 55–58 60 62–64 66 67 70 71 defined the 
VTE endpoint (DVT and or PE) as being objectively confirmed. Of the 
remainder, 3 studies34 54 69 had no objective confirmation of 
VTE and 11 studies22 25 33 35 39 48 53 59 61 65 68 did not report the 
methods for diagnosis confirmation. In terms of VTE risk 
period, half of the studies (n=23)21–26 28 35–38 40 43 44 47 49–52 56 57 59 69 
used the RAMs to predict the occurrence of VTE within 
3 months of the index hospitalisation. The remaining 
studies did not report the VTE risk period. The reported 
incidence of VTE ranged widely from 0.3%32 68 to 27.9%,46 
depending on definition, study design and study partici-
pants (eg, medical, surgical or trauma).
RAMs
The studies included in this review evaluated 
24 validated unique RAMs. The most widely 
evaluated models were the Caprini RAM (22 
studies),21 23 29–33 35 36 38 40 42 43 45 46 48 49 59 60 63 70 71 Padua predic-
tion score (16 studies),24 27 28 30 31 34 37 45 48 49 63 64 66 67 70 71 
IMPROVE models (8 studies),27 28 31 37 47 49 50 57 the Geneva 
risk score (4 studies)26–28 31 and the Kucher score (4 
studies).31 37 66 69 A summary of their associated charac-
teristics and composite clinical variables is provided in 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2 Summary of each study’s risk of bias and applicability concern using the PROBAST (Prediction model Risk Of Bias ASsessment Tool) tool—review authors’ 
judgements
Author, year
Risk of bias Concern regarding applicability Overall Overall
1. Participant 
selection 2. Predictors 3. Outcome 4. Analysis
1. Participant 
selection 2. Predictors 3. Outcomes
Risk of 
bias Applicability
Abdel- Razeq et 
al, 201021
High High High High High High High High High
Autar, 200322 High High High High High High High High High
Bahl et al, 201023 High High High High Unclear Unclear Unclear High Unclear
Barbar et al, 
201024
Low Unclear Unclear High Low Unclear Unclear High Unclear
Bilimoria et al, 
201325
Low Low Low High Low Low Low High Low
Blondon et al, 
2019a26




Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Blondon et al, 
201828
Low Unclear Unclear High Unclear Low Unclear High Unclear
Bo et al, 202029 Low Unclear Unclear Unclear High Low Low Unclear High
Chen et al, 
201830
High High High High Unclear High High High High
Cobben et al, 
201931
Unclear Unclear High High Unclear Low Unclear High Unclear
de Bastos et al, 
201632
High Low High High High Low Low High High
Dornbus et al, 
2018 (abstract)33
High Unclear High Unclear Unclear Unclear Unclear High Unclear
Elias et al, 201734 High Unclear High High Low Low High High High
Frankel et al, 
2017 (abstract)35
High Unclear Unclear High High Unclear Unclear High High
Grant et al, 
201636
High Unclear Unclear Unclear Low Low Low High Low
Greene et al, 
201637
Unclear Unclear Unclear Unclear Low Low Low Unclear Low
Hachey et al, 
201638
High Unclear Unclear High High Low High High High
Continued

























































Risk of bias Concern regarding applicability Overall Overall
1. Participant 
selection 2. Predictors 3. Outcome 4. Analysis
1. Participant 
selection 2. Predictors 3. Outcomes
Risk of 
bias Applicability
Hegsted et al, 
201339
High Unclear High High High Low Unclear High High
Hewes et al, 
201540
High Unclear Unclear High High Unclear Low High High
Ho et al, 201441 Unclear Unclear Unclear High High Unclear Unclear High High
Hu et al, 202042 Unclear Unclear Unclear Unclear High Unclear Unclear Unclear High
Krasnow et al, 
2017 (abstract)43
Unclear Unclear Unclear Unclear High Unclear Unclear Unclear High
Liu et al, 201444 Low Low Unclear Unclear High High High Unclear High
Liu et al, 201645 High Unclear High High High Low Low High High
Lobastov et al, 
201646
Unclear Unclear Unclear High High Low High High High
Mahan et al, 
201447
Low Unclear Unclear Unclear High Low Unclear Unclear High
Mlaver et al, 
202048
Unclear Unclear Unclear Unclear High Unclear Unclear Unclear High
Moumneh et al, 
202049
High Unclear Unclear Low High Low Low High High
Nafee et al, 
202050
Unclear Low Low Low Unclear Low Low Unclear Unclear
Nendaz et al, 
201451
Low Unclear Low High Low Unclear Low High Unclear
Pannucci et al, 
201253
High Unclear Unclear High High High Unclear High High
Pannucci et al, 
201452
Low Unclear High High High Low Low High High
Patell et al, 
201754
High Unclear Unclear High High Unclear Unclear High High
Rogers et al, 
200756
Unclear Unclear Unclear High Low Unclear Unclear High Unclear
Rogers et al, 
201255
High High Unclear High High High Unclear High High
Rosenberg et al, 
201457
Low Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Table 2 Continued
Continued
























































Risk of bias Concern regarding applicability Overall Overall
1. Participant 
selection 2. Predictors 3. Outcome 4. Analysis
1. Participant 
selection 2. Predictors 3. Outcomes
Risk of 
bias Applicability
Rothberg et al, 
201158
High Unclear Unclear High Low Unclear Unclear High Unclear
Shaikh et al, 
201659
High Unclear High High High Unclear High High High
Shang et al, 
202060
Low Unclear Unclear Unclear High Unclear Unclear Unclear High
Shen et al, 
202061
Unclear High Unclear Unclear High Unclear Unclear High High
Tachino et al, 
201962
High Unclear Unclear High High Unclear Unclear High High
Tian et al, 201963 High Unclear High High High High High High High
Vardi et al, 
201364
Unclear Low Low High High Low Low High High
Vaziri et al, 
201865
Unclear Unclear Unclear High High Unclear Unclear High High
Vincentelli et al, 
201866
High Low Unclear High High Low Unclear High High
Wang et al, 
202067
Low Unclear Unclear Unclear High Unclear Unclear Unclear High
Winoker et al, 
201768
High Unclear Unclear High High High High High High
Woller et al, 
201169
High High Unclear High Unclear Unclear Unclear High Unclear
Zhou et al, 
201471
Unclear Unclear Unclear High High Unclear Unclear High High
Zhou et al, 
201870
Low High High High High Unclear Unclear High High
Table 2 Continued
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Statistical methods
Statistical methods varied significantly between studies. 
Most studies reported the discrimination of the RAMs 
using a combination of the C- statistic and sensitivity or 
specificity. A minority reported calibration measures, 
such as the Hosmer- Lemeshow test.23 40 41 50
Risk of bias and applicability assessment
The overall methodological quality of the 51 included 
studies21–71 is summarised in table 2 and figure 2. The 
methodological quality of the included studies was vari-
able, with most studies having high or unclear risk of 
bias in at least one item of the PROBAST tool. The main 
sources of potential bias were related to the following 
domains:
1. Patient selection factors, such as retrospective data col-
lection, incomplete patient enrolment or unclear cri-
teria for patients receiving VTE prophylaxis.
2. Predictor and outcome bias arising from inappropri-
ate inclusion of predictors within RAMs, unclear meth-
ods of outcome definition, low event rates and missing 
predictor or outcome data.
3. Analysis factors, such as small sample sizes, inappropri-
ate handling of missing data and failure in reporting 
relevant performance measures such as calibration.
Assessment of applicability to the review question 
led to the majority of studies being classed either as 
high (n=35)21 22 29 30 32 34 35 38–49 52–55 59–68 70 71 or unclear 
(n=12)23 24 27 28 31 33 50 51 56–58 69 risk of inapplicability. These 
assessments were generally related to patient selection 
(highly selected study populations, eg, single pathologies, 
single site settings), predictors (inconsistency in defini-
tion, assessment or timing of predictors) and outcome 
determination.
Predictive performance of VTE RAMs (summary of results)
As there were a reasonable number of studies to compare, 
a summary of the C- statistics for studies involving medical, 
surgical and trauma patients respectively is presented in 
figure 3a–c, with the results grouped by RAM. Results 
of other hospital inpatients are presented in online 
supplemental appendix S4. C- statistics varied markedly 
between these studies and between models, with no 
RAM performing obviously better than other models. In 
studies evaluating a single model, C- statistics20 were some-
times weak (<0.7; 10 studies with 17 data points), often 
good (0.7–0.8; 17 studies with 20 data points) and a few 
were excellent (>0.8; 5 studies with 5 data points). There 
was marked heterogeneity between multiple studies 
evaluating the same model. Studies evaluating multiple 
(more than 3) models31 37 tended to report weak accuracy 
across all the models (C- statistic <0.7; 2 studies with 16 
data points).
Table 3 shows the sensitivity and specificity at various 
thresholds for studies involving medical, surgical and 
trauma patients respectively, with the results grouped 
by RAM. Interpretation was again limited by marked 
heterogeneity, which was exacerbated when different 
thresholds were reported by different studies evaluating 
the same model. Model accuracy was generally poor, 
with high sensitivity usually reflecting a threshold effect, 




In this systematic review of 51 observational studies evalu-
ating RAMs for predicting the risk of developing VTE in 
hospital inpatients, we found that VTE RAMs have gener-
ally weak predictive accuracy. The studies validating these 
models are heterogeneous and most have a high risk of 
bias. Lack of methodological clarity was common, leading 
to difficulty in assessing the applicability of the individual 
study results.
Interpretation of results
We were unable to undertake meta- analysis or statis-
tical examination of the causes of the observed hetero-
geneity. Potential sources of heterogeneity include 
variation in study design, the study population, how 
RAMs are implemented, outcome definition and 
measurement, and the use of thromboprophylaxis. 
Figure 2 PROBAST (Prediction model Risk Of Bias 
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Figure 3 C- statistics by model for studies involving (a) medical, (b) surgical and (c) trauma inpatients. ACS NSQIP, American 
College of Surgeons National Surgical Quality Improvement Program; CI, confidence interval; DVT, deep vein thrombosis; NR, 
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cut- off Endpoint Data source Sensitivity (95% CI) Specificity (95% CI)
MEDICAL INPATIENTS
Caprini (7 studies) Risk score ≥3 VTE Lui et al, 201645 70.9% (NR) 73.4% (NR)
  Risk score ≥3 VTE Moumneh et al, 202049 98.1% (95.6 to 99.4) 7.5% (7.1 to 8.0)
  Risk score ≥3 VTE Zhou et al, 201471 82.3% (NR) 60.4% (NR)
  Risk score ≥3 VTE Zhou et al, 201870 84.3% (NR) 66.2% (NR)
Risk score ≥5 VTE Zhou et al, 201870 57.1% (NR) 24.6% (NR)
  Risk score ≥5 VTE Grant et al, 201636 69.7% (NR) 50.28% (NR)
Risk score ≥7 VTE Grant et al, 201636 42.69% (NR) 74.71% (NR)
Risk score ≥9 VTE Grant et al, 201636 18.51% (NR) 89.03% (NR)
NR* VTE de Bastos et al, 201632 86.5% (NR) 47.0% (NR)
NR VTE Cobben et al, 201931 88.6% (NR) 21.4% (NR)
Chopard (1 study) Risk score ≥3 VTE Vincentelli et al, 201866 64.2% (38.4 to 81.9) 57.7% (63.9 to 79.4)
Geneva models (4 
studies)
Risk score ≥3 VTE Blondon et al, 201828; 
Nendaz et al, 201451
All patients:
90.0% (73.5 to 97.9)
All patients:
35.3% (32.8 to 37.8)




NR VTE Cobben et al, 201931 75.0% (NR) 34.1% (NR)
Simplified model:
Risk score ≥3
VTE Blondon et al, 2019a26 95.0% (NR) 44.0% (NR)
Simplified model:
NR
VTE Blondon et al, 2019b 
(abstract)27
86.4% (NR) NR




VTE Cobben et al, 201931 27.9% (NR) 85.4% (NR)
  7- factor model:
Risk score ≥2
VTE Moumneh et al, 202049 73.8% (68.0 to 79.0) 47.1% (46.3 to 47.9)
7- factor model:
Risk score 2–3
VTE Blondon et al, 201828; 









  7- factor model:
Risk score ≥3
VTE Blondon et al, 201828; 









  7- factor model:
Risk score ≥4
VTE Moumneh et al, 202049 24.7% (19.6 to 30.4) 85.5% (84.9 to 86.1)
7- factor model:
NR
VTE Cobben et al, 201931 63.3% (NR) 70.7% (NR)





NR VTE Cobben et al, 201931 26.4% (NR) 90.2% (NR)
Kucher (2 studies) Risk Score ≥4 VTE Vincentelli et al, 201866 25.1% (17.0 to 55.1) 92.9% (81.0 to 95.4)
NR VTE Cobben et al, 201931 28.0% (NR) 85.7% (NR)
Lecumberri (1 study) NR VTE Cobben et al, 201931 61.6% (NR) 46.3% (NR)
NAVAL (1 study) NR VTE Cobben et al, 201931 19.0% (NR) 92.7% (NR)
NICE Guidelines (1 
study)
NR VTE Cobben et al, 201931 77.6% (NR) 39.0% (NR)





















































































































cut- off Endpoint Data source Sensitivity (95% CI) Specificity (95% CI)
Risk score ≥4 VTE Blondon et al, 201828; 
Nendaz, 201451
All patients:
73.3% (54.1 to 87.7)
All patients:
51.9% (49.3 to 54.5)




Risk score ≥4 VTE Lui et al, 201645 23.4% (NR) 85.6% (NR)
  Risk score ≥4 VTE Moumneh et al, 202049 91.6% (87.6 to 94.7) 25.6% (24.9 to 26.3)
Risk score ≥4 VTE Zhou et al, 201471 30.1% (NR) 12.7% (NR)
Risk score ≥4 VTE Zhou et al, 201870 49.1% (NR) 16.2% (NR)
Risk score ≥4 VTE Vincentelli et al, 201866 52.4% (38.4 to 81.9) 72.3% (63.9 to 79.4)
  Risk score ≥4 VTE Wang et al, 202067 76.2% (NR) 61.6% (NR)
  NR VTE Blondon et al, 2019b 
(abstract)27
72.7% (NR) NR
  NR VTE Cobben et al, 201931 61.8% (NR) 48.8% (NR)
PRETEMED 
guidelines (1 study)
NR VTE Cobben et al, 201931 81.6% (NR) 24.4% (NR)
Shen 2020 (1 study) NR VTE Shen et al, 202061 77.8% (NR) 84.7% (NR)
Zakai 2013 (1 study) Model 2: NR VTE Cobben et al, 201931 63.8% (NR) 31.7% (NR)
SURGICAL INPATIENTS
Caprini (8 studies) Risk score >5 VTE Hachey et al, 201638 100% (100 to 100) 7.2% (4.1 to 11.0)
  Risk score ≥5 VTE Mlaver et al, 202048 88.9% (NR) 32.7% (NR)
  Risk score >5 VTE Shaikh et al, 201659 70.8% (48.9 to 87.4) 39.39% (37.0 to 41.9)
  Youden index 
>5.5
VTE Tian et al, 201963 76.0% (NR) 64.0% (NR)
Risk score >6 VTE Frankel et al, 2017 
(abstract)35
61.5% (NR) 59.8% (NR)
Risk score >6 VTE Shaikh et al, 201659 58.3% (36.6 to 77.9) 60.1% (57.6 to 62.5)
Risk score >7 VTE Hachey et al, 201638 100% (100 to 100) 31.4% (25 to 37.3)
Risk score >9 VTE Hachey et al, 201638 83.3% (58.3 to 100) 60.5% (54.4 to 67.3)
Risk score >9 VTE Shaikh et al, 201659 16.7% (NR) 93.3% (NR)
Risk score >10 VTE Hachey et al, 201638 75.0% (50 to 100) 69.6% (64.6 to 76.4)
Risk score >10 VTE Dornbus et al, 2018 
(abstract)33
78.9% (NR) 60.9% (NR)
Risk score >10.5 DVT or PE Lobastov et al, 201646 95.0% (NR) 73.0% (NR)
Risk score >15 † VTE Hewes et al, 201540 100% (100 to 100) 66.7% (55.0 to 78.3)
Khorana (1 study) Youden index 
>0.5
VTE Tian et al, 201963 78.0% (NR) 48.0% (NR)
Padua (2 studies) Risk score ≥4 VTE Mlaver et al, 202048 61.1% (NR) 47.4% (NR)
Youden index 
>3.5
VTE Tian et al, 201963 36.0% (NR) 93.0% (NR)
Rogers 2007 (1 study) Youden index 
>14.5
VTE Tian et al, 201963 53.0% (NR) 54.0% (NR)
TRAUMA PATIENTS
RAP (2 studies) Risk score ≥5 VTE Tachino et al, 201962 100% (86.8 to 100) 37.9% (34.6 to 41.3)
Risk score 5 to 
≤14
DVT or PE Hegsted et al, 201339  ► DVT: 82.0% (77 to 
87)
 ► PE: 71.0% (55 to 86)
 ► DVT: 57.0% (55 to 
59)
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The latter point warrants further attention. Thrombo-
prophylaxis was employed in about half (n=25) of the 
studies,21 22 24 26 28 30 34 36–38 40 42 44 46 49–52 54 57–59 64 70 71 with the 
proportion receiving thromboprophylaxis ranging from 
3.8%42 to 100%.46 50 It was not employed in 3 studies,32 61 63 
and 23 studies23 25 27 29 31 33 35 39 41 43 45 47 48 53 55 56 60 62 65–69 did 
not report on thromboprophylaxis use. The use of throm-
boprophylaxis may lead to underestimation of predictive 
accuracy if a given RAM were to predict VTE events that 
were subsequently prevented by thromboprophylaxis. 
Limited reporting of thromboprophylaxis use precludes 
further analysis of its impact on the performance of the 
RAMs.
Comparison to the existing literature
The present review is the largest and most comprehensive 
systematic review in this field to date. It includes 18 recent 
studies26–31 33 42 48–50 60–63 66 67 70 published since the comple-
tion of the previous systematic review.10 12 13 These studies 
are consistent with the previous literature in that they 
report modest performance of the assessed RAMs, with 
limitations in methodology and reporting preventing 
further analysis. The conclusion of this review therefore 
concurs with previous systematic reviews: there is insuf-
ficient evidence to recommend one RAM over another.
Strengths and limitations
This systematic review has a number of strengths. The 
review was conducted with robust methodology in accor-
dance with the PRISMA statement and the protocol was 
registered with the PROSPERO register. Clinical experts 
were involved throughout as checkers and to assess the 
validity and applicability of research during the review. 
We reported descriptive statistics to provide insight 
into the limited evidence base applicable to the subject 
matter, and the scientific concerns regarding validity of 
the data. However, there are a number of potential weak-
nesses. Decisions on study relevance, information gath-
ering and validity were unblinded and could potentially 
have been influenced by pre- formed opinions. However, 
masking is resource intensive with uncertain benefits. The 
studies of risk prediction were a combination of prospec-
tive cohorts and retrospective health database registries. 
Both have significant limitations. Retrospective studies of 
health database registries may have large numbers but 
may be limited by poor data quality and failure to accu-
rately ascertain outcomes. Prospective cohorts may have 
better quality data but with smaller numbers lack statis-
tical power. The included studies demonstrated high 
levels of heterogeneity so we were unable to undertake 
any meta- analysis.
Implications for policy, practice and future research
Guidelines from the American College of Chest Physi-
cians (ACCP)72 73 and the UK National Institute for 
Health and Care Excellence (NICE)10 suggest using 
a validated RAM to guide the decision on whether to 
prescribe thromboprophylaxis. This review identifies all 
relevant RAMs and their validation studies. The reported 
results are insufficient to recommend one RAM over 
another. A RAM with weak predictive accuracy may still be 
better than no RAM at all but it is unclear whether RAMs 
predict VTE risk better than unstructured clinical assess-
ment. Further research is clearly needed but routine use 
of thromboprophylaxis may present an insurmountable 
barrier to generating accurate and precise estimates of 
the prognostic accuracy of RAMs. The evidence that 
thromboprophylaxis is effective means that it is unethical 
to withhold thromboprophylaxis when a significant risk 
of VTE is identified. This inevitably reduces the number 




cut- off Endpoint Data source Sensitivity (95% CI) Specificity (95% CI)
  Risk score >14 DVT or PE Hegsted et al, 201339  ► DVT: 15.0% (11 to 
20)
 ► PE: 12.0% (1 to 23)
 ► DVT: 97.0% (97 to 
98)
 ► PE: 96.0% (95 to 
97)
TESS (2 studies) Risk score ≥5 VTE Rogers et al, 201255 77.4% (NR) 75.6% (NR)
Risk score <9 VTE Ho et al, 201441  ► All VTE:
97.0% (91 to 99)
 ► All VTE:
27.0% (22 to 32)
  Risk score <9 VTE Ho et al, 201441  ► Fatal and non- fatal 
PE: 97.0% (87 to 99)
 ► Fatal and non- fatal 
PE: 24.0% (20 to 
29)
  Risk score <9 VTE Ho et al, 201441  ► Fatal PE only:
100% (81 to 100)
 ► Fatal PE only:
20.0% (13 to 28)
*Paper states ‘moderate and high risk’.
†Modified Caprini model.
.DVT, deep vein thrombosis; NR, not reported; PE, pulmonary embolism; RAP, Risk Assessment Profile; TESS, Trauma Embolic Scoring 
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between risk factors and VTE events. Further studies of 
RAM accuracy will add little to our review unless they can 
address this issue.
Alternative approaches therefore need to be consid-
ered. Decision- analytic modelling can use existing data 
to explore the trade- off between the benefits and harms 
of thromboprophylaxis and identify key uncertainties 
for future primary research. The data presented in our 
review show how well RAMs predict VTE but do not tell 
us the threshold score on the RAM at which thrombopro-
phylaxis should be given to maximise prevention of VTE 
and minimise harm from bleeding. This may be a more 
important determinant of RAM effectiveness than predic-
tive accuracy for VTE. Le et al74 suggested thrombopro-
phylaxis is beneficial and cost- effective if a patient’s VTE 
risk exceeds 1%. Further work to improve RAMs to help 
stratify the risk of VTE in different types of hospitalised 
patients could focus on using decision- analytic modelling 
to compare the effects, harms and costs of giving throm-
boprophylaxis to patients with varying risk of VTE. This 
would allow determination of the risk threshold at which 
thromboprophylaxis provides optimal overall benefit.
Findings from decision- analytic modelling would 
require validation through primary research. The limita-
tions of undertaking accuracy studies in populations 
where thromboprophylaxis is routinely used mean that 
future research should focus on research that compares 
the effectiveness of different risk assessment approaches. 
Observational studies could draw on variation in practice 
to compare outcomes between different risk assessment 
methods. Alternatively, a controlled trial could compare 
risk assessment methods in low- risk patients where 
existing evidence (synthesised using decision- analytic 
modelling) suggests the benefits of thromboprophylaxis 
are uncertain.
CONCLUSIONS
We identified a number of validated RAMs for potential 
risk stratification of hospitalised inpatients. The available 
evidence is insufficient to recommend one over another.
Twitter Xavier L Griffin @xlgriffin and Kerstin de Wit @kerstindewit
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ONLINE SUPPLEMENTARY  
APPENDIX S1: LITERATURE SEARCH STRATEGY 
Table S1  Literature search strategy for the review of RAMs for VTE in hospital inpatients 
 
Database searched:  Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other 
Non-Indexed Citations, Ovid MEDLINE(R) Daily, Ovid 
MEDLINE and Versions(R) 
Platform or provider used: Ovid SP 
Date of coverage:  1946 to February 2021 
Search undertaken:   February 2021 
 
1     pulmonary embolism/ or thromboembolism/ or venous thromboembolism/ or venous thrombosis/ 
or upper extremity deep vein thrombosis/ 
2     (((venous or vein) adj (thrombosis or thromboses or thrombus or thromboembolism)) or (dvt or 
vte) or ((pulmonary or lung) adj3 (embolism or emboli or embolus or emboliz* or 
thromboembolism))).ti,ab.  
3     1 or 2  
4     letter/ or editorial/ or news/ or exp historical article/ or anecdotes as topic/ or comment/ or case 
report/ or (letter or comment).ti. 
5     randomized controlled trial/ or random*.ti,ab. 
6     4 not 5  
7     animals/ not humans/  
8     exp animals, laboratory/  
9     exp animal experimentation/  
10     exp models, animal/  
11     exp rodentia/  
12     (rat or rats or mouse or mice).ti.  
13     6 or 7 or 8 or 9 or 10 or 11 or 12  
14     3 not 13  
15     (risk* adj2 assess*).ti,ab.  
16     ((score* or scoring) adj2 (tool* or system*)).ti,ab.  
17     ((risk* or predict* or prognos*) adj4 (tool* or rule* or index* or indices or score* or scoring or 
scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab.  
18     (vienna adj5 cats).ti,ab.  
19     (vienna cancer and thrombosis study).ti,ab.  
20     trauma embolic scoring.ti,ab. 
21     tess.ti,ab.  
22     (roger* or caprini* or kucher* or cohen* or padua* or khorana* or autar).ti,ab.  
23     (well* adj2 (score* or scoring)).ti,ab.  
24     department of health.ti,ab,au.  
25     or/15-24  
26     14 and 25  
27     limit 26 to yr="2017 -Current" 
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Databases searched:  EMBASE 
Platform or provider used: Ovid SP 
Date of coverage:  1974 to February 2021 
Search undertaken:   February 2021 
 
1     thromboembolism/ or venous thromboembolism/ or vein thrombosis/ or deep veinthrombosis/ or 
leg thrombosis/ or lower extremity deep vein thrombosis/ or postoperativethrombosis/ or lung 
embolism/ or upper extremity deep vein thrombosis/  
2     (((venous or vein) adj (thrombosis or thromboses or thrombus or thromboembolism)) or (dvt or 
vte) or ((pulmonary or lung) adj3 (embolism or emboli or embolus or emboliz* or 
thromboembolism))).ti,ab.  
3     1 or 2  
4     letter.pt. or letter/ or note.pt. or editorial.pt. or case report/ or case study/ or (letter or 
comment*).ti.  
5     randomized controlled trial/ or random*.ti,ab.  
6     4 not 5  
7     animal/ not human/  
8     nonhuman/  
9     exp animal experiment/ or exp experimental animal/  
10     animal model/  
11     exp rodent/  
12     (rat or rats or mouse or mice).ti.  
13     6 or 7 or 8 or 9 or 10 or 11 or 12  
14     3 not 13  
15     (risk* adj2 assess*).ti,ab.  
16     ((score* or scoring) adj2 (tool* or system*)).ti,ab.  
17     ((risk* or predict* or prognos*) adj4 (tool* or rule* or index* or indices or score* or scoring or 
scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab.  
18     (vienna adj5 cats).ti,ab.  
19     (vienna cancer and thrombosis study).ti,ab.  
20     trauma embolic scoring.ti,ab.  
21     tess.ti,ab.  
22     (roger* or caprini* or kucher* or cohen* or padua* or khorana* or autar).ti,ab.  
23     (well* adj2 (score* or scoring)).ti,ab.  
24     department of health.ti,ab,au.  
25     or/15-24  
26     14 and 25  
27     limit 26 to yr="2017 -Current"  
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Databases searched:  Cochrane CENTRAL Register of Randomised Controlled 
Trials & Cochrane Database of Systematic Reviews 
Platform or provider used: www.thecochranelibrary.com 
Date of coverage:  Inception to February 2021 
Search undertaken:   February 2021 
 
#1. MeSH descriptor: [venous thromboembolism] this term only 
#2. MeSH descriptor: [pulmonary embolism] this term only 
#3. MeSH descriptor: [venous thrombosis] this term only 
#4. MeSH descriptor: [thromboembolism] this term only 
#5. MeSH descriptor: [upper extremity deep vein thrombosis] this term only 
#6. ((*venous or *vein) next (thrombosis or thromboses or thrombus or thromboembolism) or dvt or 
vte or (pulmonary or lung) near/3 (embolism or emboli or embolus or emboliz* or 
thromboembolism)):ti,ab 
#7. #1 or #2 or #3 or #4 or #6 
#8. (risk* near/2 assess*):ti,ab  
#9. ((score* or scoring) near/2 (tool* or system*)):ti,ab  
#10. ((risk* or predict* or prognos*) near/4 (tool* or rule* or index* or indices or score* or scoring or 
scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)):ti,ab  
#11. (vienna near/5 cats):ti,ab  
#12. (vienna cancer and thrombosis study):ti,ab  
#13. trauma embolic scoring:ti,ab  
#14. tess:ti,ab  
#15. (roger* or caprini* or kucher* or cohen* or padua* or khorana* or autar):ti,ab  
#16. (well* near/2 (score* or scoring)):ti,ab  
#17. (department of health):ti,ab  
#18. (or #8-#17)  
#19. #7 and #18 with Publication Year from 2017 to 21 
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APPENDIX S2:  LIST OF EXCLUDED STUDIES WITH RATIONALE 
 Authors, year Reason for exclusion 
1.  Alikhan et al., 2004 1 Derivation only 
2.  Alper et al., 2018 2 Not a RAM for predicting the risk of developing VTE in 
hospital inpatients 
3.  Arcelus et al., 1991 3 No relevant/useable outcome data 
4.  Arpaia et al., 2020 4 Not a RAM for predicting the risk of developing VTE in 
hospital inpatients 
5.  Bagot et al., 2010 5 No relevant/useable outcome data 
6.  Bellizzi et al., 2018 6 No relevant/useable outcome data 
7.  Blondon et al., 2020 7 Duplicate of included study (Blondon et al., 2019a) 
8.  Blondon et al., 2017 8 Abstract of an included full-text study 
9.  Caprini et al., 2001 9 Review 
10.  Chen et al., 2018 10 Not available (foreign language) 
11.  Chopard et al., 2006 11 No relevant/useable outcome data 
12.  Coelho et al., 2020 12 Not a RAM for predicting the risk of developing VTE in 
hospital inpatients 
13.  Dang et al., 2019 13 Derivation only 
14.  Davis and Intagliata, 2018 14 No relevant/useable outcome data 
15.  Depietri et al., 2018 15 No relevant/useable outcome data 
16.  Ellis et al., 2019 16 No relevant/useable outcome data 
17.  Fadoi Foundation, 2020 17 Trial protocol (no results) 
18.  Ferreira et al., 2018 18 No relevant/useable outcome data 
19.  Ferreira et al., 2017 19 No relevant/useable outcome data 
20.  Fritz et al., 2021 20 No relevant/useable outcome data 
21.  Gibson et al., 2017 21 RAM involves diagnostic testing 
22.  Girardi et al., 2018 22 Not a RAM for predicting the risk of developing VTE in 
hospital inpatients 
23.  Grzelak et al., 2019 23 Not a RAM for predicting the risk of developing VTE in 
hospital inpatients 
24.  Hostler et al., 2016 24 No relevant/useable outcome data 
25.  Hu, 2018 25 No relevant/useable outcome data 
26.  Koren et al., 2017 26 Not a RAM for predicting the risk of developing VTE in 
hospital inpatients 
27.  Kucher et al., 2005 27 No relevant/useable outcome data 
28.  Lecumberri et al., 2008 28 No relevant/useable outcome data 
29.  Luo and Zhang, 2017 29 Not available (foreign language) 
30.  Maynard et al., 2010 30 No relevant/useable outcome data 
31.  McCaffrey et al., 2007 31 No relevant/useable outcome data 
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32.  Meizoso et al., 2017 32 Derivation only 
33.  Monti et al., 2019 33 Abstract of included full text paper 
34.  Mull et al., 2017 34 Review 
35.  Nafee et al., 2018 35 Abstract of included full text paper 
36.  Nnadi et al., 2017 36 No relevant/useable outcome data 
37.  Obi et al., 2015 37 Critical care patients 
38.  Pannucci et al., 2017 38 Review 
39.  Rafizadeh et al., 2016 39 No relevant/useable outcome data 
40.  Rastogi et al., 2020 40 No relevant/useable outcome data 
41.  Razak et al., 2019 41 Not a RAM for predicting the risk of developing VTE in 
hospital inpatients 
42.  Robert-Ebadi et al., 2017 42 Not a RAM for predicting the risk of developing VTE in 
hospital inpatients 
43.  Salim et al., 2018 43 No relevant/useable outcome data 
44.  Samama et al., 2006 44 Expert opinion 
45.  Shrotriya et al., 2018 45 Not a RAM for predicting the risk of developing VTE in 
hospital inpatients 
46.  Smilg Nicolas et al., 2018 46 No relevant/useable outcome data 
47.  Spirk et al., 2017 47 No relevant/useable outcome data 
48.  Spyropoulos et al., 2020 48 RAM involves diagnostic testing 
49.  Spyropoulos et al., 2011 49 Derivation only 
50.  Stuck et al., 2017 50 Review 
51.  Tadesse et al., 2020 51 No relevant/useable outcome data 
52.  Taha et al., 2020 52 No relevant/useable outcome data 
53.  Tung et al., 2020 53 No relevant/useable outcome data 
54.  Veith et al., 2019 54 No relevant/useable outcome data 
55.  Winoker et al., 2017 55 Abstract of an included full-text study 
56.  Yale et al., 2005 56 Derivation only 
57.  Ye et al., 2017 57 Review 
58.  Zakai et al., 2013 58 Derivation only 
59.  Zambelli et al., 2020 59 Not a RAM for predicting the risk of developing VTE in 
hospital inpatients 
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APPENDIX S3:  WIDELY EVALUATED GENERIC RAMS, THEIR ASSOCIATED CHARACTERISTICS AND COMPOSITE CLINICAL 
VARIABLES 














General       
Author, year Caprini 20051 Barbar 20102 Tapson 20073 Spyropoulos 20114 Chopard 20065 Kucher 20056 
Applicable cohort Surgical and medical Medical Medical Medical Medical Surgical and medical 
Design Ordinal with cumulative 
score 
Dichotomous variables 
with cumulative score 
Dichotomous variables 
with VTE probability 
estimate 
Dichotomous variables 
with VTE probability 
estimate 
Dichotomous variables 
with cumulative score 
Dichotomous variables 
with cumulative score 
Number of VTE risk variables 31 11 4 7 19 8 
C-statistic (range) across medical, 
surgical and trauma cohorts 
0.53 - 0.87 
(12 studies) 
0.594 - 0.756 
(7 studies) 
0.57 – 0.65 
(2 studies) 






When is pharmacological 
thromboprophylaxis recommended? 
 
Score 5 Score 4 No specific threshold 
Identified 
No specific threshold 
identified 
Score 3 Score 4 
Clinical Variables       
Patient related       
Active cancer  Yes Yes Yes Yes Yes Yes (Major risk) 
Age Yes Yes (70) Yes (60) Yes (60) Yes (60) Yes (70 Minor risk) 
Dehydration No No No No Yes No 
Thrombophilia Yes (generic and named 
conditions) 
Yes (generic) Yes (generic) Yes (generic) Yes (generic) Yes (Major risk) 
Obesity  Yes (25kg/m2) Yes (30kg/m2) No No Yes (30kg/m2) Yes (30kg/m2 Minor risk) 
Comorbidity Yes (1 to 5 points for 
individual comorbidities) 
Yes (1 point each for 
several individual 
comorbidities) 




Prior VTE Yes Yes Yes Yes Yes Yes (Major risk) 
Family history of VTE Yes No No No No No 
Use of HRT Yes Yes No No Yes Yes (Minor risk) 
Use of oestrogen containing 
contraceptive therapy 
Yes Yes No No Yes Yes (Minor risk) 
Varicose veins Yes No No No No No 
Pregnancy or postpartum period No No No No Yes No 
Unexplained stillbirth or 
spontaneous abortions 
Yes (3 spontaneous 
abortions) 
No No No No No 
Current swollen legs Yes No No No Yes No 
Current central venous access Yes No No No No No 
Recent major surgery Yes (<1 month) Yes (<1 month) No No No No 
Recent use of plaster cast 
immobilisation 
Yes (<1 month) No No No No No 
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Lower limb paralysis Yes No No Yes No No 
Travel related No No No No Yes (>6hours) No 
Admission related       
Reduced mobility Yes (variable points) Yes No Yes (7days) Yes (3 days) Yes (Minor risk) 
Arthroplasty surgery Yes No No No No No 
Hip fracture Yes No No No No No 
Pelvic or lower limb surgery Yes (arthroscopic) No No No No No 
Total anaesthetic and surgical 
time 
Yes (45mins) No No No No Yes (60mins intermediate 
risk) 
Acute surgical admission  No No No No No No 
Acute infection  No Yes No No Yes No 
Acute rheumatologic disorder No Yes No No Yes No 
Critical care admission No No No Yes No No 
Surgery leading to reduced 
mobility 
Yes No No No No No 
Other       
‘Other risk factors’ Yes No No No No No 
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APPENDIX S4:  SUMMARY OF PREDICTIVE PERFORMANCE FOR STUDIES INVOLVING HOSPITAL INPATIENTS WHO 
REQUIRED CARE FOR CANCER, STROKE, BURN INJURIES AND SEPSIS OR WERE A MIXED 
MEDICAL/SURGICAL COHORT 
 
Data source Endpoint Incidence Risk assessment model Threshold or cut-off Predictive performance 
C-statistic (95% CI) Sensitivity (95% CI) Specificity (95% CI) 
MIXED INPATIENTS 
Autar, 200322 DVT 18.9% •Novel (Autar, 2003) Risk score ≤6 NR 100% (NR) 100% (NR) 
   •Novel (Autar, 2003) Risk score 7-10 NR 86.0% (NR) 68.0% (NR) 
   •Novel (Autar, 2003) Risk score 11-14 NR 68.0% (NR) 31.0% (NR) 
   •Novel (Autar, 2003) Risk score ≥15 NR 25.0% (NR) 10.0% (NR) 
Elias, 201734 VTE 0.8% •Padua (automated) Risk score ≥5 0.81 (0.79, 0.83) 85.4% (NR) 53.3% (NR) 
Chen, 201830 DVT NA •Caprini Risk score ≥4 NR 73.8% (NR) 64.7% (NR) 
   •Caprini Risk score ≥5 NR 62.8% (NR) 82.6% (NR) 
   •Padua Risk score ≥3 NR 53.5% (NR) 82.1% (NR) 
   •Padua Risk score ≥4 NR 42.1% (NR) 92.5% (NR) 
Bo, 202029 DVT 0.9% •Caprini Risk score ≥3.5 0.74 (0.71, 0.77) 75.0% (NR) 62.0% (NR) 
CANCER INPATIENTS 
Abdel-Razeq, 201021 VTE 3.5% •Caprini (modified) Risk score ≥3 NR 100% (NR) 9.2% (NR) 
   •Caprini (modified) Risk score ≥5 NR 57.1% (NR) 53.2% (NR) 
Patell, 201754 VTE 3.8% •Khorana Risk score ≥3 NR 18.9%  (NR) 87.2%  (NR) 
Hu, 202042 VTE NA •Caprini Risk score ≥5 0.71 (0.66, 0.75) 82.4% (NR) 46.2% (NR) 
•Khorana Risk score ≥2 0.58 (0.53, 0.63) 35.3% (NR) 78.7% (NR) 
Shang, 202060 VTE NA •Caprini 2009 Risk score ≥3 0.72 (0.70, 0.74) 83.5% (NR) 52.7% (NR) 
•Caprini 2013 Risk score ≥5 0.80 (0.78, 0.82) 80.9% (NR) 65.9% (NR) 
BURNS INPATIENTS 
Pannucci, 201253 VTE 1.0% •Novel (Pannucci 2012) NR 0.75 NR NR 
POST-STROKE INPATIENTS 
Liu, 201444 DVT 10.5% •Post-stroke DVT Prediction System NR 0.65 (0.59, 0.70) NR NR 
SEPSIS INPATIENTS 
Vardi, 201364 VTE 1.3% •Padua  NR •All patients 





   •Padua NR •No prophylaxis 





CI, confidence interval; DVT, deep vein thrombosis; NA, not applicable; NR, not reported; VTE, venous thromboembolism 
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